Document is current
Any future updates will be listed below
-
Authors
Nepal, Yogesh
Francian, Alexandra
Flores-Garcia, Yevel
Roberts, Bryce T.
David, Sunil A.
Zavala, Fidel
Chackerian, Bryce
-
Funding
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (R01 AI169739, R01 AI169739, R01 AI169739, R01 AI169739, HHSN272201800049C, R01 AI169739, R01 AI169739)
National Institute of General Medical Sciences (K12 GM088021, P20 GM121176)
- License Information
-
More Information
Article History
Received: 3 March 2025
Accepted: 20 July 2025
First Online: 30 July 2025
Competing interests
: B.C. has equity in Metaphore Biotechnologies. S.A.D. is affiliated with ViroVax LLC, which holds proprietary rights over the Cquim-MA adjuvant. F.Z. serves as an Associate Editor of this journal and had no role in the peer-review or decision to publish this manuscript. F.Z. declares no financial competing interests. All other authors (Y.N., A.F., Y.F-G., and B.T.R.) declare no competing financial or non-financial competing interests.
